Design Therapeutics Expands Board of Directors with Key Appointments
June 07, 2021 16:05 ET
|
Design Therapeutics, Inc.
CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced the...
Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results
May 10, 2021 16:05 ET
|
Design Therapeutics, Inc.
Successful $276 Million IPO Completed to Advance GeneTACTM Programs for Friedreich Ataxia and Myotonic Dystrophy Type-1 Toward Clinical Development Company On-track to Initiate Phase 1 Clinical Trial...
Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 30, 2021 16:05 ET
|
Design Therapeutics, Inc.
CARLSBAD, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN) (“Design”), a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small...
Design Therapeutics Announces Pricing of Initial Public Offering
March 25, 2021 23:56 ET
|
Design Therapeutics, Inc.
CARLSBAD, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc., a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of...